Other equities analysts have also recently issued research reports about the stock. Wedbush reissued a buy rating and set a $253.00 target price on shares of Intercept Pharmaceuticals in a research report on Friday, December 22nd. Oppenheimer reissued a hold rating on shares of Intercept Pharmaceuticals in a research report on Thursday, February 15th. Citigroup set a $74.00 target price on shares of Intercept Pharmaceuticals and gave the stock a hold rating in a research report on Thursday, December 21st. ValuEngine cut shares of Intercept Pharmaceuticals from a sell rating to a strong sell rating in a research report on Friday, February 2nd. Finally, BMO Capital Markets lifted their target price on shares of Intercept Pharmaceuticals from $152.00 to $155.00 and gave the stock an outperform rating in a research report on Thursday, February 15th. Four equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $128.75.
Intercept Pharmaceuticals stock opened at $61.52 on Wednesday. Intercept Pharmaceuticals has a 52 week low of $51.05 and a 52 week high of $135.59. The company has a current ratio of 4.31, a quick ratio of 4.31 and a debt-to-equity ratio of 21.71. The company has a market cap of $1,548.64, a price-to-earnings ratio of -4.28 and a beta of -1.92.
A number of institutional investors have recently added to or reduced their stakes in ICPT. Senvest Management LLC purchased a new position in Intercept Pharmaceuticals in the 3rd quarter valued at approximately $33,883,000. First Trust Advisors LP grew its stake in Intercept Pharmaceuticals by 101.5% in the 4th quarter. First Trust Advisors LP now owns 605,454 shares of the biopharmaceutical company’s stock valued at $35,371,000 after buying an additional 304,999 shares in the last quarter. Pinnacle Associates Ltd. purchased a new position in Intercept Pharmaceuticals in the 4th quarter valued at approximately $12,577,000. Sarissa Capital Management LP purchased a new position in Intercept Pharmaceuticals in the 4th quarter valued at approximately $10,649,000. Finally, Emerald Advisers Inc. PA purchased a new position in Intercept Pharmaceuticals in the 4th quarter valued at approximately $9,497,000. Institutional investors and hedge funds own 74.27% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by WKRB News and is owned by of WKRB News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.wkrb13.com/2018/04/01/intercept-pharmaceuticals-icpt-rating-reiterated-by-needham-company-llc.html.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.